Table 3D.
Non-serous vs serous disease
| Antigen | Non-serous | Serous | Bivariable model | Multivariable model | ||
|---|---|---|---|---|---|---|
| N=63 | N=63 | Signif.1 | Signif.2 | Signif1 | Signif2 | |
| NASP | 16 (25%) | 42 (67%) | < 0.001 | < 0.001 | 0.02 | - - - |
| MRE11 | 40 (65%) | 51 (81%) | 0.05 | - - - | 0.71 | - - - |
| RCAS1 | 33 (53%) | 48 (76%) | 0.01 | 0.04 | 0.19 | - - - |
| RAD50 | 36 (58%) | 55 (87%) | 0.001 | 0.006 | 0.22 | - - - |
| Her2 | 14 (22%) | 23 (37%) | 0.09 | - - - | 0.12 | - - - |
| NBS1 | 14 (23%) | 39 (62%) | < 0.001 | < 0.001 | 0.02 | - - - |
| eIF5A | 48 (77%) | 58 (92%) | 0.05 | - - - | 0.82 | - - - |
| p53 | 20 (32%) | 37 (59%) | 0.003 | 0.02 | 0.30 | - - - |
1
Significance of the marker based on bootstrapped logistic regression model.
2
Adjusted for multiple comparisons using Holm’s method.